Aptose Biosciences Inc. (TSE:APS – Free Report) (NASDAQ:APTO) – Investment analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Aptose Biosciences in a note issued to investors on Wednesday, November 20th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($2.51) per share for the year. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q4 2024 earnings at ($0.49) EPS.
Aptose Biosciences Stock Down 20.6 %
APS opened at C$0.27 on Monday. Aptose Biosciences has a twelve month low of C$0.19 and a twelve month high of C$3.90. The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.80. The business has a 50 day moving average price of C$0.51 and a 200 day moving average price of C$0.84. The firm has a market cap of C$4.89 million, a P/E ratio of -0.05 and a beta of 1.36.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More
- Five stocks we like better than Aptose Biosciences
- Most active stocks: Dollar volume vs share volume
- Disney’s Magic Strategy: Reinventing the House of Mouse
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What Are Some of the Best Large-Cap Stocks to Buy?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
